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Abstract
Anorectal disorders such as dyssynergic defecation, fecal incontinence, levator ani syndrome and 
solitary rectal ulcer syndrome are common, and affect both the adult and pediatric populations. 
Although they are treated with several treatment approaches, over the last two decades, 
biofeedback therapy using visual and verbal feedback techniques has emerged as an useful option. 
Because it is safe, it is commonly recommended. However, the clinical efficacy of biofeedback 
therapy in adults and children is not clearly known, and there is a lack of critical appraisal of the 
techniques used and the outcomes of biofeedback therapy for these disorders. The American 
Neurogastroenterology and Motility Society and the European Society of Neurogastroenterology 
and Motility convened a task force to examine the indications, study performance characteristics, 
methodologies used and the efficacy of biofeedback therapy, and to provide evidence-based 
recommendations. Based on the strength of evidence, biofeedback therapy is recommended for the 
short term and long term treatment of constipation with dyssynergic defecation (Level I, Grade A), 
and for the treatment of fecal incontinence (Level II, Grade B). Biofeedback therapy may be 
useful in the short-term treatment of Levator Ani Syndrome with dyssynergic defecation (Level II, 
Grade B), and solitary rectal ulcer syndrome with dyssynergic defecation (Level III, Grade C), but 
the evidence is fair. Evidence does not support the use of biofeedback for the treatment of 
childhood constipation (Level 1, Grade D).
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syndrome
INTRODUCTION
Anorectal disorders such as dyssynergic defecation, fecal incontinence and levator ani 
syndrome are common and affect up to 25% of the adult and pediatric populations. They 
significantly affect quality of life and pose a major health care burden (1–3). Although these 
disorders are treated with several approaches including laxatives, antidiarrheals, botulinum 
toxin or dextranomer injections, electrical and sacral nerve stimulations and surgery (1,2,4), 
biofeedback therapy using visual and verbal feedback techniques has emerged as a useful 
treatment option. However, a critical appraisal of the techniques used and the outcomes of 
biofeedback therapy are lacking.
The American Neurogastroenterology and Motility Society and the European Society of 
Neurogastroenterology and Motility convened a task force to examine the indications, study 
performance characteristics, methodologies used and the scientific basis, noting especially 
the results of randomized controlled trials and the impact of biofeedback therapy on patient 
reported outcomes, objective measurements and quality of life. These measures were used to 
provide evidence-based recommendations regarding the clinical utility and efficacy of 
biofeedback therapy for dyssynergic defecation, fecal incontinence, levator ani syndrome, 
solitary rectal ulcer syndrome and childhood constipation.
Pubmed, Embase, Medline, and PsychInfo databases from inception to August 2014 were 
used to identify appropriate studies in adults and children. Inclusion criteria included 
randomized controlled trials (RCTs), and those that compared biofeedback with standard 
care, placebo or no treatment. If unavailable, uncontrolled studies were examined. Treatment 
recommendations were based on grading recommended by the U.S. Preventive Services 
Task Force (5).
BIOFEEDBACK THERAPY FOR DYSSYNERGIC DEFECATION
Introduction
Neuromuscular dysfunction of the defecation unit can lead to disordered or difficult 
defecation. Dyssynergic defecation (DD) is the most common defecation disorder that 
affects about 40% of patients with chronic constipation (6). It is an acquired behavioral 
disorder where the act of stooling is uncoordinated or dyssynergic (6). Physiologic testing 
may demonstrate one or more abnormalities when attempting to defecate: (a) paradoxical 
anal contraction, (b) incomplete anal relaxation, (c) inadequate push effort, or (d) elevated 
threshold for the sensation of stooling (rectal hyposensitivity). Whole gut transit time may 
be delayed in up to 2/3rds of these patients, but this is believed to be secondary to the outlet 
dysfunction rather than a cause of defecatory dysfunction (6–8).
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Patients with chronic constipation and DD who fulfill the criteria shown in Table 1 are 
eligible for biofeedback therapy (6–8). Contraindications include severe neurological 
disorders, inability to sit on a commode, developmental disability and visual impairment.
Study Performance
Technical Aspects—The goal of biofeedback training is to improve bowel function by 
restoring a normal pattern of defecation. Biofeedback therapy is an instrument-based 
learning process that is based on “operant conditioning” techniques. The governing principle 
is that any behavior when reinforced repeatedly can be learned and perfected. In patients 
with dyssynergic defecation, the goal of biofeedback training is three-fold (8–10):
i. To correct the dyssynergia or incoordination of the abdominal, rectal, puborectalis 
and anal sphincter muscles in order to achieve a normal and complete evacuation 
(Fig. 1).
ii. To facilitate normal evacuation by simulated defecation training using balloons.
iii. To enhance rectal sensory perception in patients with impaired rectal sensation.
(i) Correct dyssynergia and improve rectoanal coordination: The purpose of this training 
is to produce a coordinated defecatory movement that consists of an abdominal push effort 
synchronized with relaxation of the pelvic floor (Fig. 1). This is achieved by manometric or 
electromyographic (EMG)-guided training of the abdominal push effort (diaphragmatic and 
abdominus rectus muscle training) together with anal relaxation.
The subject should be seated on a commode with the manometry/EMG probe in situ. The 
monitor display of the pressure/EMG changes from the rectum and anal canal provides 
visual feedback and facilitates learning (Fig. 1). First, their posture and breathing techniques 
during attempted defecation are corrected. Next, at least 10–15 bearing down maneuvers is 
performed. Additional bearing down maneuvers may be performed with a 60 cc balloon 
inflated in the rectum in order to provide a sensation of stooling. After few sessions the 
patient is encouraged to perform these maneuvers without visual or verbal feedback.
(ii) Facilitate simulated defecation training: The goal here is to teach the subject to expel 
a 50 ml water or air-filled balloon by using gentle traction to supplement the patient’s 
efforts, preferably in the seated position on a commode.
(iii) Sensory training: The objective of this optional training is to improve the thresholds 
for rectal sensory perception and to promote better awareness for stooling in patients with 
rectal hyposensitivity (9,11). This is performed by intermittent inflation of the balloon in the 
rectum. The goal is to teach the subject to perceive a lower volume of balloon distention but 
with the same intensity as experienced with a higher volume. Thus, by repeated inflations 
and deflations newer sensory thresholds can be established (8,9).
Duration and Frequency of Training: The number of sessions and frequency of sessions 
should be customized for each patient. Typically, training sessions are performed biweekly 
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and each session takes one hour, and on average, 4 to 6 training sessions are required; 
periodic reinforcements at additional intervals may provide benefit (9,12), but its role has 
not been examined. Patients are encouraged to practice diaphragmatic breathing and 
attempted defecation maneuvers at home for at least 15 minutes, two or three times a day 
(11–15). Training is discontinued when patients demonstrate: (i) consistent coordinated 
pattern of defecation with anal relaxation; (ii) improved stooling habit; and (iii) normal 
balloon expulsion time.
Devices and Techniques for Biofeedback: Because biofeedback is an instrument-based 
learning technique, several devices and methods are available including solid-state 
manometry systems, catheters with microballoons or perfusion ports, anal EMG probes, and 
home training devices (8). A manometry probe with microtransducers located in anal canal 
and a rectal balloon has the advantage of displaying rectal and anal pressure changes 
accurately and this may facilitate training of rectal propulsive forces (increases in rectal 
pressure produced by the diaphragm and abdominal muscle contraction), anal relaxation and 
sensory training. EMG probes provide information on the striated anal muscles but do not 
provide information on rectal propulsive forces.
Efficacy of Biofeedback Therapy and Randomized Controlled Trials (Table 2)
Several randomized controlled trials have been reported in adults with dyssynergic 
defecation and are summarized in Table 2 (11–15). Although there are methodological 
differences between the studies including recruitment criteria, end points and outcome 
measures, all studies have concluded that biofeedback therapy is superior to controlled 
treatment approaches including diet, exercise and laxatives (11,12), polyethylene glycol 
(15), diazepam/placebo tablets (14), balloon defecation therapy (16) and sham feedback 
therapy (11).
Both short-term and one year long-term outcome studies have shown that biofeedback is 
superior to standard therapy alone in patients with DD (12). A meta-analysis of 7 studies 
involving biofeedback compared to any other treatment suggested that biofeedback 
conferred a six-fold increase in the odds of treatment success (odds ratio 5·861 (95% CI, 2·2 
to 15·8); (17). Predictors for successful therapy include harder stool consistency (P = 0.009), 
greater willingness to participate, higher resting anal sphincter pressure, and prolonged 
balloon expulsion time, with sensitivity and specificity of 0.79 to 0.81, respectively. A 
longer duration of laxative use was associated with poor outcome (18). DD is associated 
with significant impairment in QOL (19). In a prospective RCT of 100 patients, biofeedback 
therapy, administered at home or in-office improved most QOL domains in patients with 
DD (20).
Strengths & Confounding Issues
Biofeedback therapy is a labor-intensive approach but has no adverse effects. However, it is 
only offered in a few centers and is performed by nurse therapists or physiotherapists. In 
order to treat the vast number of constipated patients in the community, a home based, self-
training program is desirable. Uncontrolled studies of home trainers have reported that 
biofeedback is useful (21,22). However, there is no standard or approved device. A recent 
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RCT showed that home biofeedback is as useful as office biofeedback therapy in improving 
symptoms and anorectal function (23). Also, treatment success may be best defined by a 
combination of improvement in bowel function such as ≥1 CSBM/week + correction of 
dyssynergia pattern, but such measures have not been used in clinical trials.
The mechanism of action of biofeedback therapy is not fully understood. Improvements in 
defecation appear to be mediated by enhanced rectal propulsive forces and by anal and 
pelvic floor relaxation and by improved sensory thresholds (11–15,24). Recent studies using 
bidirectional cortical evoked potentials and transcranial magnetic stimulations have revealed 
significant bi-directional brain-gut dysfunction in patients with dyssynergic defecation (25), 
and biofeedback appears to improve these dysfunctions (26).
Because biofeedback is an instrument-based treatment, standardization of both equipment 
and protocols is desirable. At present, both EMG and pressure-based biofeedback therapy 
protocols have been used, and both appear to be efficacious, but comparative trials are 
lacking. EMG probes are cheaper, more durable and usually provide one or two- channel 
display whereas manometric systems are more expensive, provide multiple channel display 
and because they have a balloon and rectal sensor they can facilitate recto-anal coordination 
and sensory training. A recent systematic review concluded that there is currently 
“insufficient evidence to allow firm conclusions regarding efficacy and safety of 
biofeedback for treatment of chronic constipation (27). However, this review addressed the 
use of biofeedback in all patients with constipation, for example, it included studies that 
evaluated biofeedback therapy for conditions that are not always associated with disordered 
defecation (eg, rectal prolapse and slow transit constipation). In fact, biofeedback therapy 
does not benefit constipated patients without dyssynergic defecation (13). Hence, including 
patients with these disorders as well as many other suboptimal and non-randomized older 
studies in the meta analysis, most likely diluted the benefit of biofeedback therapy, and led 
to an inappropriate conclusion regarding its use in defecation disorders. Lastly, the review 
determined that blinding was suboptimal and there was a risk of bias; however, the ability to 
blind subjects to treatment assignment in behavioral trials is limited and the risk of bias 
definition used for drug trials cannot be applied to behavioral trials. Hence, these factors 
should not weigh against the rigorous quality of randomized controlled trials for 
biofeedback therapy. It is essential that only patients who fulfill the criteria for dyssynergic 
defecation be offered this treatment modality.
RECOMMENDATION
Biofeedback therapy is recommended for the short term and long term treatment of 
constipation with dyssynergic defecation. Level I, Grade A.
BIOFEEDBACK THERAPY FOR FECAL INCONTINENCE
Introduction
Fecal Incontinence affects approximately 8.3% of the population and its treatment remains 
unsatisfactory. Biofeedback has been shown to be a useful treatment approach (1,2,4).
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Indications—Patients with FI who have not responded to conservative medical treatment 
measures including a trial of antidiarrheals or fiber supplements. Patients must have 
adequate cognitive ability and be motivated to participate in this training program. 
Contraindications include neurological disorders such as spinal cord injury, severe internal 
anal sphincter injuries resulting in absence of resting anal canal pressure, dementia, 
developmental disability, uncontrolled psychotic disorder, age younger than 8 years, and 
visual impairment.
Study Performance
Technical Aspects—Biofeedback involves the use of electronic or mechanical devices to 
provide augmented awareness of physiological responses to patients and their therapists to 
facilitate neuromuscular retraining. The goals are to correct the physiological deficits that 
contribute to FI by (1) improving the strength and isolation of pelvic floor muscles, (2) 
improving the ability to sense weak distentions of the rectum and contract pelvic floor 
muscles in response to these distentions, and/or (3) improving the ability to tolerate larger 
rectal distentions without experiencing uncontrollable urge sensations (28–34).
(i) Anal and pelvic floor muscle training: First, patients are instructed to isolate the anal 
sphincter and puborectalis muscles and improve its strength by using modified Kegel 
exercises in the sitting or lying position with a probe in situ. Visual and verbal feedback 
techniques are used to reinforce the maneuvers, as they are being performed. The anal and 
rectal pressure changes displayed on the monitor provides visual feedback to the patient. 
The verbal feedback is provided by the physician/nurse therapist and consists of either 
complimenting the patient for performing a correct maneuver or rectifying any errors. The 
patient is instructed to squeeze and to maintain the squeeze for as long as possible. During 
the maneuver, the patient observes the monitor and is educated about the changes in anal 
pressure/EMG activity. For comparison, a normal recording is shown (32). As the sphincter 
strength improves, the patient is encouraged to maintain a voluntary contraction for at least 
30 s. Patients are instructed not to use their abdominal or gluteal muscles to achieve a 
voluntary squeeze. After a few sessions, the patient is encouraged to perform these 
maneuvers without visual feedback (32,33). Also, the patient is instructed to perform 
squeeze exercises at home for at least 20 min, two to three times a day, and to perform about 
20 squeeze maneuvers per session. Training may be discontinued when patients demonstrate 
(1) reduction in the number of incontinence episodes; (2) improvement in anal squeeze 
pressure and rectoanal coordination when squeezing. Patients also receive sensory-motor 
coordination training. The objective here is to achieve a maximum voluntary squeeze in less 
than 1 second after inflation of a rectal balloon and to control the reflex anal relaxation by 
consciously contracting the sphincter muscles (28,29,32).
(ii) Sensory Training: Patients found to have an impaired rectal sensation may benefit from 
sensory training (29–31). In brief, a series of progressively smaller balloon inflations are 
performed, starting with the volume that induced a sensation of urge to defecate, and 
decreasing by 5–10 ml with each successive distention. The patient is instructed to respond 
to the rectal distention by squeezing their anal sphincters. When the patient fails to perceive 
the balloon inflation, this defines the sensory threshold. Sensory discrimination training is 
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used to train the patient to recognize and respond to lower balloon volumes; the balloon is 
distended with slightly higher, and on others trials slightly lower volumes than the current 
threshold. The patient is encouraged to focus on any sensation they feel in their rectum even 
if it is not the sensation they were expecting, and to squeeze in response to it. They are 
encouraged to watch for these sensations when they are at home (between training sessions) 
and to always squeeze when they think they feel something, even if they are not sure. They 
are told that it does not hurt to squeeze extra times if there is a chance this could prevent an 
accident.
(iii) Urge Resistance Training: Patients who have accidents that are preceded by a strong, 
uncontrollable urge to defecate are desensitized to the sensations of rectal balloon inflation 
by distending the rectal balloon in a step-wise fashion with progressively larger volumes of 
air until a strong urge is experienced. Once this strong urge threshold is identified, some air 
is removed from the balloon and the patient is taught to relax using a deep breathing 
technique. They are encouraged to use relaxation to counteract the urge sensation while the 
balloon is gradually inflated again. This process is repeated several times during the training 
session. The goal is to teach the patient how to use relaxation as a coping mechanism to 
enable them to tolerate larger volumes of balloon inflation. For home practice, they are 
taught to use relaxation to counteract urge sensations at home and to “Walk; don’t run” to 
the toilet when they feel an urge.
Duration and Frequency of Training: Typically, treatment sessions are performed 
biweekly (32,35), although different intervals may be used. The number of sessions may be 
customized for each patient but usually six sessions are performed. Each session takes 
approximately one hour.
Devices and Techniques for Biofeedback: Commonly a manometry system (pressure 
sensors) or EMG probe is used (32,33,35,36), and rarely an anal ultrasound probe (34) or a 
home training device has been used (33).
Efficacy of Biofeedback therapy & Randomized Controlled Trials (Table 3)
RCTs of biofeedback for FI have yielded inconsistent results (30–34, 37,38,39). Two earlier 
studies (33,34) showed no benefit for biofeedback compared to pelvic floor exercises taught 
by digital rectal exam, while a third study (32) showed a clear superiority for biofeedback 
compared to pelvic floor exercises taught verbally. In the third study, which had the 
strongest design, patients with severe FI (at least weekly solid or liquid stool accidents) first 
underwent a one-month screening period on conservative management, and patients who 
achieved adequate relief were excluded from further participation (32). The remaining 108 
patients underwent biofeedback training by an experienced biofeedback therapist during 6 
biweekly sessions and were reassessed at 3 months and 12 months follow up. In the intent to 
treat analysis, 76% of biofeedback patients vs. 41% of pelvic floor exercise patients 
improved at 3 months follow up (p<0.001) and patients using biofeedback had greater 
reductions in Fecal Incontinence Severity Index (FISI) scores. Results were well maintained 
at 12 months in this and in an independent, uncontrolled study (36). Anal sphincter exercises 
(pelvic floor muscle training) and biofeedback therapy have been used alone and in 
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combination for the treatment of FI. Anal sphincter exercises are performed to strengthen 
the puborectalis and EAS muscles (32,33,35,36). A single-center, randomized controlled 
study indicated that a regimen of pelvic floor exercises with biofeedback was nearly twice as 
effective as pelvic floor exercises alone, with 44% vs. 21% of patients achieving complete 
continence at 3 months, respectively (P = 0.008) (35). In a more recent randomized study 
comparing 2 different pelvic floor exercise regimens, both with biofeedback, 59 of the 69 
patients (86%) had improved continence with 20% fully continent, with no statistically 
significant differences between exercise regimens (40). A 2012 systematic review of 
randomized or quasi-randomized controlled trials of patients performing anal sphincter 
exercises and/or receiving biofeedback and/or surface electrical stimulation of the anal 
sphincter concluded that the addition of biofeedback or electrical stimulation was superior to 
exercise alone in patients who had previously failed to respond to other conservative 
treatments, but overall there was insufficient evidence for biofeedback therapy or one 
method of therapy (35).
In patients with reduced rectal sensation, there is objective evidence that 
biofeedback therapy can improve rectal sensation (29,36,41) and shorten the 
latency between rectal distention and contraction of the external anal sphincter 
(41). While anal resting and squeeze pressure increased after some studies of 
biofeedback therapy, effects were relatively small (35). The American College of 
Gastroenterology (1), and the Rome Foundation (7) recommends biofeedback for 
the treatment of FI.
Strengths & Confounding Issues
It is important to recognize some differences in study methodology among the key RCTs of 
biofeedback therapy that are summarized in table 3. One study (32) systematically screened 
patients for one month and excluded those who achieved adequate relief with conservative 
management, and required that patients have at least moderately severe FI (two or more 
episodes of FI per week) prior to treatment. However, others (33,34) included patients with 
mild FI and did not exclude those who could benefit from conservative treatment alone. Two 
studies (31,37) were underpowered, and the one (31) used a cross-over design but did not 
demonstrate return to baseline following the first intervention. Thus, further research is 
needed to standardize the treatment protocols and the training of biofeedback therapists. 
Treatment success is best defined by an improvement in bowel function such as 50% 
reduction in episodes of fecal incontinence, but this measure has not been used in clinical 
trials.
Alternative/comparative approaches
Pelvic floor exercises alone are nearly always recommended to patients with FI, but there is 
little consensus on how they should be taught. There are no known RCTs (33). In some 
recent studies, pelvic floor exercises were taught by a health care provider during a digital 
rectal examination, and reductions in FI from baseline were comparable to those achieved 
with biofeedback training using electronic devices (33). Electrical stimulation of the anal 
mucosa is not effective when used as the sole treatment for FI (38). However, mucosal 
electrical stimulation may augment the effects of biofeedback (39) and merits further RCT.
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Biofeedback therapy is recommended for the short term and long term treatment of fecal 
incontinence. Level II, Grade B.
BIOFEEDBACK THERAPY FOR LEVATOR ANI SYNDROME AND SOLITARY 
RECTAL ULCER SYNDROME
INTRODUCTION
Levator ani syndrome (LAS) is characterized by chronic or recurrent anorectal pain or 
aching lasting at least 20 min, without any structural or systemic disease (7). Its exact 
prevalence is unknown. It is part of a spectrum of painful anorectal disorders. LAS is 
associated with tenderness of the levator ani muscle during digital rectal examination (7), 
and increased anal canal resting pressures. In a recent study, 85% of patients with LAS 
showed dyssynergic defecation, i.e., paradoxical contraction or failure to relax the pelvic 
floor muscles when straining to defecate plus inability to evacuate a water-filled rectal 
balloon (42).
Solitary Rectal Ulcer Syndrome (SRUS), is characterized by single or multiple ulcers in the 
rectum with specific histological inflammatory changes, and is associated with symptoms of 
excessive straining, chronic or recurring anal or rectal discomfort, use of digital maneuvers 
to defecate, and frequent blood and mucus discharge (43, 44). Manometric studies have 
revealed dyssynergia in up to 2/3rds of patients with SRUS (44, 45), and this may develop 
secondary to painful defecation. It has been suggested that excessive straining over years 
may lead to rectal mucosal intussusception; repeated trauma of the prolapsing rectal mucosa 
together with dyssynergia may lead to a stretch injury or ischemic ulceration (44, 45).
Indications
- Levator Ani Syndrome: (i) Patients unresponsive to standard therapies including 
antispasmodics and muscle relaxants. (ii) Absence of structural or inflammatory 
causes of chronic anorectal pain and pelvic pain. (iii) Demonstrable tenderness 
of levator ani muscle on digital rectal exam.
- Solitary Rectal Ulcer Syndrome: (i) Endoscopically and histologically proven 
SRUS. (ii) SRUS unresponsive to behavioral measures including avoiding 
excessive straining, laxatives, topical therapies such as sucralfate or 5-ASA.
Study performance and technical aspects—Studies of biofeedback therapy for these 
disorders have used methods, techniques and protocols similar to those described under the 
section of biofeedback therapy for dyssynergic defecation (11–14, 43, 44, 46).
Efficacy of Biofeedback Therapy & randomized Controlled Trials
Reports of biofeedback treatment for chronic functional anorectal pain have shown 
inconsistent results, and most of these were small and uncontrolled (46) However, a recent 
RCT of 157 well-characterized patients with LAS compared three treatments: biofeedback 
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to teach pelvic floor muscle relaxation, electrogalvanic stimulation (EGS) to relax the pelvic 
floor, and digital massage of the levator muscles (42). The primary outcome measure was 
the subjects’ report of adequate pain relief. Key to the interpretation of the study was an a 
priori decision to test for tenderness when traction was applied to the levator ani muscles 
during digital rectal examination, and patients were stratified into the three treatment arms 
based on the presence or absence of tenderness. Among patients with tenderness on physical 
examination, adequate relief was reported by 87% with biofeedback, 45% with EGS and 
22% with digital massage. However, none of these three treatments were effective in 
patients who did not report tenderness on physical examination (42). The mixed results 
reported in previous biofeedback studies most likely were a consequence of failure to 
stratify patients based on the presence or absence of levator ani tenderness.
Biofeedback therapy has also been used to treat SRUS in open, short-term, small sized (less 
than 20 patients) studies (43,44). Inclusion criteria, physiological investigations and 
outcome parameters were variable. Biofeedback therapy was associated with symptom 
improvement in at least two thirds of patients with some histological improvement (44). 
Most notably, the highest successful outcome was reported when SRUS was associated with 
DD (44).
Strengths and confounding issues
The biofeedback training protocol that was developed originally to treat dyssynergic 
defecation also appears to be effective for the treatment of LAS in one large RCT, and 
possibly useful in SRUS based on uncontrolled trials. These observations suggest that DD 
may be a key pathophysiological dysfunction in both LAS and SRUS, although it is 
unknown why tense striated pelvic floor muscles cause pain in some patients, bleeding and 
ulceration with mucosal intussusception in others and only difficulty with defecation in the 
majority. Further characterization of the underlying pathophysiology of these disorders may 
shed more insights, and importantly confirmatory RCTs are needed for LAS and SRUS.
RECOMMENDATION
Biofeedback therapy may be useful for the short-term treatment of Levator Ani Syndrome 
with dyssynergic defecation (Level II, Grade B) and solitary rectal ulcer syndrome with 
dyssynergic defecation (Level III, Grade C), but the evidence is fair.
BIOFEEDBACK THERAPY FOR PEDIATRIC FUNCTIONAL CONSTIPATION
Introduction
Functional constipation (FC) and overflow fecal incontinence (FI) are commonly 
encountered in the pediatric population, with a worldwide prevalence of 3% (47) In most 
children, the purposeful or subconscious withholding of stool after having experienced the 
passage of a hard, painful or frightening bowel movement leads to FC. The retentive child 
learns to contract the pelvic floor, the anal sphincter, and the gluteal muscles in response to 
the urge to defecate so as to avoid defecation (3). The withholding behavior creates a vicious 
cycle of progressive accumulation of feces and hardening of stool, which when untreated 
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causes stretching of the rectal wall and development of a megarectum. This in turn results in 
overflow FI, loss of rectal sensation and eventually loss of normal urge to defecate (3).
Anorectal manometry can demonstrate abnormal defecation dynamics in 50% of children 
with FC (48,49), and rectal barostat studies show impaired rectal sensation and higher rectal 
compliance (50). Conventional treatment consists of educating the parent and the child 
regarding correct defecation dynamics and behavioral interventions, such as toilet training, 
laxatives and/or enemas (51). Despite these interventions, only half of all children with 
constipation, followed for 6–12 months evacuate regular stools without laxatives (52). Thus, 
biofeedback therapy may be an option in children with chronic defecation disorders.
Indication
Functional constipation with dyssynergic defecation, which is unresponsive to conventional 
treatment.
Study Performance Characteristics
Technical aspects—The objective is to achieve normal evacuation by using visual and 
verbal biofeedback techniques and correcting the inadequate coordination of pelvic floor 
muscles and anal sphincter and by improving the awareness for stooling (urge to defecate). 
Biofeedback teaches children how to relax the external anal sphincter (EAS) with visual 
reinforcement (anorectal manometry and electromyography) in response to abdominal 
straining. The equipment used and principles of training including the duration and 
frequency of therapy sessions are similar to those described above for adult patients 
undergoing biofeedback therapy for dyssynergic defecation. After reliable and consistent 
relaxation of EAS is accomplished, children are instructed to do the same without visual 
feedback.
Efficacy of biofeedback therapy & Randomized Controlled Trials (Table 4)
Several RCTs have been reported in children and have also been systematically assessed in a 
recent ESPGHAN/NASPGHAN guideline (51). There are significant methodological 
differences among the published studies including recruitment criteria, end points and 
outcome measures. These are summarized in Table 4 (48, 49, 53–57). One single study 
included children with functional nonretentive fecal incontinence (FNRFI) and one study 
evaluated children with FI due to a myelomeningocele, and both were excluded from this 
analysis.
Seven trials compared biofeedback to conventional therapy, including education, toilet 
training and laxatives (58) Two studies only used surface EMG to provide biofeedback 
whereas others used anorectal manometry and EMG. Sample sizes ranged from 21 to 192 
subjects, and only children who were older than 5 years were enrolled. Children should be at 
least 5 year old before starting biofeedback therapy (48, 49, 55, 56, 57), as attention span 
and ability to focus and not being intimidated by laboratory environment are important 
factors that contribute to treatment success. Three studies were conducted in outpatient 
clinics in USA, two in Europe, one in South America and one in Australia (Table 4). Four 
studies included children with chronic constipation and FI and the other three studies 
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enrolled children with constipation associated with FI and pelvic floor dyssynergia. Follow-
up varied from 6–18 months. Since allocation concealment was unclear in 5 studies and 
double blinding is not possible due to the nature of performing trials with behavioral 
interventions, the standard definitions for a risk of bias used in conventional drug studies 
cannot be directly applied to these studies. One study had a high risk of incomplete outcome 
data (51, 52). Number of biofeedback sessions depended on how soon the child learned to 
relax the EAS. Different outcome measures were used across all studies, such as defecation 
frequency, episodes of FI, use of laxatives and results of anorectal manometry, but the 
number of children improved or not cured was used as an outcome measure in all trials (51, 
52).
A RCT by Loening-Baucke (48) compared biofeedback with conventional therapy 
(education, toilet training, laxatives) in 129 children (5–18 years of age) in USA, in an 
outpatient setting, with a follow-up period of four years. Whether the treatment allocation 
was concealed was unclear, and because blinding is not possible, meta-analysis adjudged a 
possible risk of bias. Patients were rated as recovered if they had ≥3 bowel movements per 
week and ≤2 FI episodes per month while off laxatives for at least one month. Results 
showed that biofeedback did not improve long-term recovery rates when compared to 
conventional therapy alone.
Another RCT by Van der Plas et al (49) evaluated the additional effect of biofeedback 
compared to conventional treatment (education, toilet training and laxatives) in 192 children 
with chronic constipation (5–16 years of age) in the Netherlands, in an outpatient tertiary 
care setting, with a follow-up period of 1 year. Although treatment allocation was concealed, 
blinding was not possible. Treatment was considered successful if the patients achieved 
three or more bowel movements per week and had less than two episodes of FI per month 
while not receiving laxatives for 4 weeks. The results showed that additional biofeedback 
compared to conventional therapy did not result in higher success rates in chronically 
constipated children. Furthermore, achievement of normal defecation dynamics was not 
associated with success.
After pooling the data and excluding the trials that either enrolled children with FNRFI or 
children with FI due to organic causes, there were no significant differences between 
biofeedback plus conventional treatment when compared to conventional treatment alone 
after 12 months for the number of children designated as cured or improved (OR 1.13; 95% 
CI 0.77–1.66) and 18 months (OR 1.42; 95% CI 0.79–2.53).
Strengths & Confounding issues
In these different RCTs, neither adverse effects nor cost-effectiveness analysis were 
reported, although risk is very small. Studies in constipated children have shown that 
abnormal defecation dynamics can begin at any age in childhood (58). Thus, it is possible 
that in the majority of these patients withholding behavior due to painful defecation could be 
avoided by early and adequate therapeutic intervention with laxatives and reassurance alone 
(59). Because many children are diagnosed late and fail to respond to laxative therapy, 
alternative therapies are often sought either by caregivers or medical providers. Although 
several pediatric studies show that biofeedback therapy results in an improvement of 
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defecation dynamics and other parameters like maximal defecation pressure (49,55), it 
appears that the long-term treatment success does not differ between most children who 
have received biofeedback versus those who have received conventional therapy.
The results of biofeedback therapy in children are at odds with those in the adult literature. 
As discussed earlier in this article, several RCTs in adult patients have demonstrated that 
biofeedback therapy is effective in improving bowel symptoms and in correcting 
dyssynergic defecation. It is unclear why biofeedback therapy in children is less successful. 
The absence of clinical improvement after correction of abnormal defecation dynamics, 
could suggest that dyssynergic defecation plays a less crucial role in the pathophysiology of 
pediatric constipation or the nature of illness and its natural history is different in children. 
For example, children may learn to stop withholding more easily or the cognitive skills 
required for biofeedback to succeed might be more complex and challenging making clinical 
outcomes less favorable. Thus, based on published evidence, although biofeedback therapy 
is useful, it does not provide additional benefit over conventional treatment of constipation 
in most children, either with or without FI (51).
RECOMMENDATION
Biofeedback therapy is not recommended for the routine treatment of children with 
functional constipation, with or without overflow fecal incontinence. Level 1, Grade D.
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The rectal and anal pressure changes, and manometric patterns in a patient with constipation 
and dyssynergic defecation, before and after biofeedback showing paradoxical anal 
contraction at baseline that improved after 5 sessions of biofeedback therapy
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B. The anorectal pressure changes in the same patient (2A) after 4 sessions of biofeedback 
therapy for fecal incontinence. The patient now demonstrates a coordinated squeeze 
response with a significant and sustained increase in the anal sphincter pressure, and without 
any rise in intrarectal pressure.
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Table 1
Diagnostic Criteria for Dyssynergic Defecation (6,7):
A. Patients must satisfy the diagnostic criteria for functional chronic constipation (Rome III) and
B. Patients must have dyssynergic pattern of defecation (Types 1–4), which is defined as paradoxical increase in anal sphincter 
pressure (anal contraction) or less than 20% relaxation of the resting anal sphincter pressure or inadequate propulsive forces based 
on manometry (8), radiologic imaging or EMG.
C. Patients must satisfy one or more of the following criteria*:
1. Inability to expel an artificial stool (50 ml water filled balloon) within one to two minutes.
2. Inability to evacuate or ≥50% retention of barium during defecography.
3. *Some laboratories use a prolonged colonic transit time, i.e. greater than 5 markers (≥20% marker retention) on a plain 
abdominal x-ray taken 120 hours after ingestion of one radiopaque marker capsule containing 24 radio opaque markers.
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